AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
Factors to Consider The Zacks Consensus Estimate for AbbVie's total revenues stands at $11.99 billion, while our estimate is $11.93 billion. AbbVie's top line is being driven by sales of new immunology drugs, Skyrizi and Rinvoq. The Zacks Consensus Estimate for Skyrizi sales is pegged at $1.97 billion, while the same for Rinvoq stands at $1.05 billion. Our model estimates for Skyrizi and Rinvoq sales are pegged at $1.93 billion and $1.00 billion, respectively. This strength in revenue of both these drugs is mainly driven by approvals of the drugs in new indications. With these approvals, sales of these drugs could be higher in 2024 and potentially replace the company's flagship drug, Humira, which has been facing generic erosion in the United States since last year. The drug lost exclusivity in ex-U.S. territories in 2018. The Zacks Consensus Estimate for Humira sales is pegged at $2.23 billion, while our estimate stands at around $2.24 billion. We expect J&J-partnered Imbr
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Intrauterine Devices Market To Reach USD 10.5 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Peptide Synthesis: Global Markets Projected to Reach $157.5 Billion by 2028, According to BCC Research Analysis [Yahoo! Finance]Yahoo! Finance
- [Latest] Global Lipid Nanoparticles Market Size/Share Worth USD 1,899.8 Million by 2033 at a 14.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]Latest
- Global $11 Billion Non-Hodgkin Lymphoma Market Outlook, 2024-2029: Focus on T-cell Lymphoma and Immunotherapies [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 5/3/24 - Form 10-Q
- 4/26/24 - Form 8-K
- 4/3/24 - Form 8-K
- ABBV's page on the SEC website